TY  - JOUR
AU  - Tomić, Milan
AU  - Novaković, Aleksandra
AU  - Milojević, Predrag
AU  - Nenezić, Dragoslav
AU  - Stojanović, Ivan
AU  - Gajin, Predrag
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2936
AB  - More than 50 years ago, vitamin K antagonists were the only available oral anticoagulants. Since their application involves a number of limitations, it was necessary to develop new oral anticoagulant drugs and introduce them into clinical practice. These drugs have many advantages over vitamin K antagonists, including rapid onset/offset, a small number of interactions with other drugs and food, simplified dosing and predictable pharmacokinetics, eliminating the need for daily laboratory monitoring. In addition, new oral anticoagulant drugs act selectively on a single coagulation factor. Currently, the following drugs are approved for use: direct thrombin inhibitor, dabigatran etexilate, direct factor Xa inhibitor, rivaroxaban, apixaban and edoxaban. Dabigatran etexilate and apixaban are approved for the primary prevention of venous thromboembolism in adult patients undergoing elective surgery of total hip or knee replacement, while in addition to these anticoagulants edoxaban is approved for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. For the treatment and prevention of recurrent deep vein thrombosis dabigatran etexilate, rivaroxaban and edoxaban are approved. In addition, rivaroxaban is approved for the secondary prevention of atherothrombotic events in patients with acute coronary syndrome.
AB  - Više od 50 godina, antagonisti vitamina K bili su jedini dostupni oralni antikoagulantni lekovi. S obzirom na to da njihova primena podrazumeva brojna ograničenja, bilo je neophodno razviti i uvesti u kliničku praksu nove oralne antikoagulantne lekove. Ovi lekovi imaju brojne prednosti u poređenju s antagonistima vitamina K, koje uključuju brz početak i prestanak dejstva, mali broj interakcija s drugim lekovima i hranom, pojednostavljen način doziranja, kao i predvidivu farmakokinetiku, čime se eliminiše potreba za svakodnevnim laboratorijskim praćenjem. Osim toga, novi oralni antikoagulantni lekovi deluju selektivno samo na jedan faktor koagulacije. Trenutno su odobreni za upotrebu direktni inhibitor trombina, dabigatran eteksilat, kao i direktni inhibitori faktora Xa, rivaroksaban, edoksaban i apiksaban. Dabigatran eteksilat i apiksaban odobreni su za primarnu prevenciju venske tromboembolije kod odraslih pacijenata koji se podvrgavaju elektivnom hirurškom zahvatu totalne zamene kuka ili kolena, dok je za prevenciju moždanog udara i sistemske embolije kod odraslih pacijenata sa nevalvularnom atrijalnom fibrilacijom, pored navedenih antikoagulantnih lekova, odobren i edoksaban. Za terapiju i prevenciju rekurentne duboke venske tromboze odobreni su dabigatran eteksilat, rivaroksaban i edoksaban. Osim toga, rivaroksaban je odobren i za sekundarnu prevenciju aterotrombotičkih događaja nakon akutnog koronarnog sindroma.
PB  - Srpsko lekarsko društvo - Okružna podružnica Kragujevac, Kragujevac
T2  - Medicinski časopis
T1  - Direct oral anticoagulant drugs in the prophylaxis and therapy of thromboembolic diseases
T1  - Direktni oralni antikoagulantni lekovi u profilaksi i terapiji tromboembolijskih bolesti
VL  - 51
IS  - 3
SP  - 89
EP  - 97
DO  - 10.5937/mckg51-15563
ER  - 

@article{
author = "Tomić, Milan and Novaković, Aleksandra and Milojević, Predrag and Nenezić, Dragoslav and Stojanović, Ivan and Gajin, Predrag",
year = "2017",
abstract = "More than 50 years ago, vitamin K antagonists were the only available oral anticoagulants. Since their application involves a number of limitations, it was necessary to develop new oral anticoagulant drugs and introduce them into clinical practice. These drugs have many advantages over vitamin K antagonists, including rapid onset/offset, a small number of interactions with other drugs and food, simplified dosing and predictable pharmacokinetics, eliminating the need for daily laboratory monitoring. In addition, new oral anticoagulant drugs act selectively on a single coagulation factor. Currently, the following drugs are approved for use: direct thrombin inhibitor, dabigatran etexilate, direct factor Xa inhibitor, rivaroxaban, apixaban and edoxaban. Dabigatran etexilate and apixaban are approved for the primary prevention of venous thromboembolism in adult patients undergoing elective surgery of total hip or knee replacement, while in addition to these anticoagulants edoxaban is approved for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. For the treatment and prevention of recurrent deep vein thrombosis dabigatran etexilate, rivaroxaban and edoxaban are approved. In addition, rivaroxaban is approved for the secondary prevention of atherothrombotic events in patients with acute coronary syndrome., Više od 50 godina, antagonisti vitamina K bili su jedini dostupni oralni antikoagulantni lekovi. S obzirom na to da njihova primena podrazumeva brojna ograničenja, bilo je neophodno razviti i uvesti u kliničku praksu nove oralne antikoagulantne lekove. Ovi lekovi imaju brojne prednosti u poređenju s antagonistima vitamina K, koje uključuju brz početak i prestanak dejstva, mali broj interakcija s drugim lekovima i hranom, pojednostavljen način doziranja, kao i predvidivu farmakokinetiku, čime se eliminiše potreba za svakodnevnim laboratorijskim praćenjem. Osim toga, novi oralni antikoagulantni lekovi deluju selektivno samo na jedan faktor koagulacije. Trenutno su odobreni za upotrebu direktni inhibitor trombina, dabigatran eteksilat, kao i direktni inhibitori faktora Xa, rivaroksaban, edoksaban i apiksaban. Dabigatran eteksilat i apiksaban odobreni su za primarnu prevenciju venske tromboembolije kod odraslih pacijenata koji se podvrgavaju elektivnom hirurškom zahvatu totalne zamene kuka ili kolena, dok je za prevenciju moždanog udara i sistemske embolije kod odraslih pacijenata sa nevalvularnom atrijalnom fibrilacijom, pored navedenih antikoagulantnih lekova, odobren i edoksaban. Za terapiju i prevenciju rekurentne duboke venske tromboze odobreni su dabigatran eteksilat, rivaroksaban i edoksaban. Osim toga, rivaroksaban je odobren i za sekundarnu prevenciju aterotrombotičkih događaja nakon akutnog koronarnog sindroma.",
publisher = "Srpsko lekarsko društvo - Okružna podružnica Kragujevac, Kragujevac",
journal = "Medicinski časopis",
title = "Direct oral anticoagulant drugs in the prophylaxis and therapy of thromboembolic diseases, Direktni oralni antikoagulantni lekovi u profilaksi i terapiji tromboembolijskih bolesti",
volume = "51",
number = "3",
pages = "89-97",
doi = "10.5937/mckg51-15563"
}

Tomić, M., Novaković, A., Milojević, P., Nenezić, D., Stojanović, I.,& Gajin, P.. (2017). Direct oral anticoagulant drugs in the prophylaxis and therapy of thromboembolic diseases. in Medicinski časopis
Srpsko lekarsko društvo - Okružna podružnica Kragujevac, Kragujevac., 51(3), 89-97.
https://doi.org/10.5937/mckg51-15563

Tomić M, Novaković A, Milojević P, Nenezić D, Stojanović I, Gajin P. Direct oral anticoagulant drugs in the prophylaxis and therapy of thromboembolic diseases. in Medicinski časopis. 2017;51(3):89-97.
doi:10.5937/mckg51-15563 .

Tomić, Milan, Novaković, Aleksandra, Milojević, Predrag, Nenezić, Dragoslav, Stojanović, Ivan, Gajin, Predrag, "Direct oral anticoagulant drugs in the prophylaxis and therapy of thromboembolic diseases" in Medicinski časopis, 51, no. 3 (2017):89-97,
https://doi.org/10.5937/mckg51-15563 . .

TY  - JOUR
AU  - Nenezić, Dragoslav
AU  - Tanasković, Slobodan
AU  - Gajin, Predrag
AU  - Ilijevski, Nenad
AU  - Novaković, Aleksandra
AU  - Radak, Đorđe
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2423
AB  - Introduction: In this report, we aim to present a rare case of isolated internal iliac artery aneurysm with associated left ureteric obstruction and consequent hydronephrosis. Case report: A 66-year-old male patient was admitted for occasional pain in the lower back that appeared one month earlier. CT arteriography revealed isolated internal iliac artery (diameter 99 mm) with ureteral obstruction, hydroureter and left kidney hydronephrosis occurrence. Aneurysm was resected, after six months the patient was doing well. Bearing in mind that 77% of the patients with isolated internal iliac artery have symptoms caused by aneurysmal compression on adjacent organs, we wanted to highlight that despite the amazing expansion of endovascular procedures in the last decades, its therapeutic effect in isolated internal iliac artery's treatment is to a great extent limited since compression symptoms cannot be solved. Conclusion: Open surgery remains the gold standard for isolated internal iliac artery's treatment considering significant limitations of endovascular procedures due to the inability to eliminate problems caused by compression.
PB  - Sage Publications Ltd, London
T2  - Vascular Pharmacology
T1  - A rare case of large isolated internal iliac artery aneurysm with ureteral obstruction and hydronephrosis: Compression symptoms are limitation for endovascular procedures
VL  - 23
IS  - 2
SP  - 170
EP  - 175
DO  - 10.1177/1708538114533963
ER  - 

@article{
author = "Nenezić, Dragoslav and Tanasković, Slobodan and Gajin, Predrag and Ilijevski, Nenad and Novaković, Aleksandra and Radak, Đorđe",
year = "2015",
abstract = "Introduction: In this report, we aim to present a rare case of isolated internal iliac artery aneurysm with associated left ureteric obstruction and consequent hydronephrosis. Case report: A 66-year-old male patient was admitted for occasional pain in the lower back that appeared one month earlier. CT arteriography revealed isolated internal iliac artery (diameter 99 mm) with ureteral obstruction, hydroureter and left kidney hydronephrosis occurrence. Aneurysm was resected, after six months the patient was doing well. Bearing in mind that 77% of the patients with isolated internal iliac artery have symptoms caused by aneurysmal compression on adjacent organs, we wanted to highlight that despite the amazing expansion of endovascular procedures in the last decades, its therapeutic effect in isolated internal iliac artery's treatment is to a great extent limited since compression symptoms cannot be solved. Conclusion: Open surgery remains the gold standard for isolated internal iliac artery's treatment considering significant limitations of endovascular procedures due to the inability to eliminate problems caused by compression.",
publisher = "Sage Publications Ltd, London",
journal = "Vascular Pharmacology",
title = "A rare case of large isolated internal iliac artery aneurysm with ureteral obstruction and hydronephrosis: Compression symptoms are limitation for endovascular procedures",
volume = "23",
number = "2",
pages = "170-175",
doi = "10.1177/1708538114533963"
}

Nenezić, D., Tanasković, S., Gajin, P., Ilijevski, N., Novaković, A.,& Radak, Đ.. (2015). A rare case of large isolated internal iliac artery aneurysm with ureteral obstruction and hydronephrosis: Compression symptoms are limitation for endovascular procedures. in Vascular Pharmacology
Sage Publications Ltd, London., 23(2), 170-175.
https://doi.org/10.1177/1708538114533963

Nenezić D, Tanasković S, Gajin P, Ilijevski N, Novaković A, Radak Đ. A rare case of large isolated internal iliac artery aneurysm with ureteral obstruction and hydronephrosis: Compression symptoms are limitation for endovascular procedures. in Vascular Pharmacology. 2015;23(2):170-175.
doi:10.1177/1708538114533963 .

Nenezić, Dragoslav, Tanasković, Slobodan, Gajin, Predrag, Ilijevski, Nenad, Novaković, Aleksandra, Radak, Đorđe, "A rare case of large isolated internal iliac artery aneurysm with ureteral obstruction and hydronephrosis: Compression symptoms are limitation for endovascular procedures" in Vascular Pharmacology, 23, no. 2 (2015):170-175,
https://doi.org/10.1177/1708538114533963 . .

TY  - JOUR
AU  - Nenezić, Dragoslav
AU  - Radak, Đorđe
AU  - Jocić, Dario
AU  - Gajin, Predrag
AU  - Tanasković, Slobodan
AU  - Novaković, Aleksandra
AU  - Matić, Predrag
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2287
AB  - Introduction Acute lower limb ischemia results from thrombosis or embolization of diseased native artery or previously implanted bypass graft. When this occurs, several options are available to restore blood flow: catheter-directed thrombolysis, mechanical thrombectomy or open surgery. Fundamental reasons to apply percutaneous interventions are avoiding open procedures in high risk patients, and avoiding difficult dissection through scar tissue. Case Outline A 67-year-old male was admitted at our Institution for critical limb ischemia. After performed angiography the diagnosis of occluded femoropopliteal graft was established. Occlusion was resolved by catheter-directed thrombolysis with plasmin. Culprit lesions were treated by angioplasty. Conclusion Our patient underwent a successful thrombolysis of occluded femoropopliteal graft with locally-delivered human plasmin.
AB  - Uvod Ishemija donjih ekstremiteta je posledica tromboze ili embolizacije obolele nativne arterije ili implantiranog grafta. Postoji nekoliko načina lečenja ishemije: tromboliza kateterom, mehanička trombektomija i hirurško lečenje. Osnovni razlozi za primenu perkutanih intervencija jeste izbegavanje klasičnog hirurškog lečenja kod bolesnika s visokim rizikom, kao i izbegavanje preparisanja krvnog suda u ožiljku. Prikaz bolesnika Muškarac star 67 godina primljen je u bolnicu zbog kritične ishemije donjih ekstremiteta. Po učinjenoj angiografiji dijagnostikovana je tromboza femoropoplitealnog grafta. Okluzija je rešena primenom plazmina uz upotrebu intraarterijskog katetera. Stenoze koje su otkrivene posle trombolize lečene su angioplastikom. Zaključak Trombolizom uz primenu plazmina i intraarterijskog katetera uspešno je izlečena okluzija femoropoplitealnog grafta.
PB  - Srpsko lekarsko društvo, Beograd
T2  - Srpski arhiv za celokupno lekarstvo
T1  - Thrombolysis of occluded femoropopliteal graft with locally delivered human plasmin
T1  - Tromboliza okludiranog femoropoplitealnog grafta lokalno primenjenim humanim plazminom
VL  - 142
IS  - 5-6
SP  - 342
EP  - 346
DO  - 10.2298/SARH1406342N
ER  - 

@article{
author = "Nenezić, Dragoslav and Radak, Đorđe and Jocić, Dario and Gajin, Predrag and Tanasković, Slobodan and Novaković, Aleksandra and Matić, Predrag",
year = "2014",
abstract = "Introduction Acute lower limb ischemia results from thrombosis or embolization of diseased native artery or previously implanted bypass graft. When this occurs, several options are available to restore blood flow: catheter-directed thrombolysis, mechanical thrombectomy or open surgery. Fundamental reasons to apply percutaneous interventions are avoiding open procedures in high risk patients, and avoiding difficult dissection through scar tissue. Case Outline A 67-year-old male was admitted at our Institution for critical limb ischemia. After performed angiography the diagnosis of occluded femoropopliteal graft was established. Occlusion was resolved by catheter-directed thrombolysis with plasmin. Culprit lesions were treated by angioplasty. Conclusion Our patient underwent a successful thrombolysis of occluded femoropopliteal graft with locally-delivered human plasmin., Uvod Ishemija donjih ekstremiteta je posledica tromboze ili embolizacije obolele nativne arterije ili implantiranog grafta. Postoji nekoliko načina lečenja ishemije: tromboliza kateterom, mehanička trombektomija i hirurško lečenje. Osnovni razlozi za primenu perkutanih intervencija jeste izbegavanje klasičnog hirurškog lečenja kod bolesnika s visokim rizikom, kao i izbegavanje preparisanja krvnog suda u ožiljku. Prikaz bolesnika Muškarac star 67 godina primljen je u bolnicu zbog kritične ishemije donjih ekstremiteta. Po učinjenoj angiografiji dijagnostikovana je tromboza femoropoplitealnog grafta. Okluzija je rešena primenom plazmina uz upotrebu intraarterijskog katetera. Stenoze koje su otkrivene posle trombolize lečene su angioplastikom. Zaključak Trombolizom uz primenu plazmina i intraarterijskog katetera uspešno je izlečena okluzija femoropoplitealnog grafta.",
publisher = "Srpsko lekarsko društvo, Beograd",
journal = "Srpski arhiv za celokupno lekarstvo",
title = "Thrombolysis of occluded femoropopliteal graft with locally delivered human plasmin, Tromboliza okludiranog femoropoplitealnog grafta lokalno primenjenim humanim plazminom",
volume = "142",
number = "5-6",
pages = "342-346",
doi = "10.2298/SARH1406342N"
}

Nenezić, D., Radak, Đ., Jocić, D., Gajin, P., Tanasković, S., Novaković, A.,& Matić, P.. (2014). Thrombolysis of occluded femoropopliteal graft with locally delivered human plasmin. in Srpski arhiv za celokupno lekarstvo
Srpsko lekarsko društvo, Beograd., 142(5-6), 342-346.
https://doi.org/10.2298/SARH1406342N

Nenezić D, Radak Đ, Jocić D, Gajin P, Tanasković S, Novaković A, Matić P. Thrombolysis of occluded femoropopliteal graft with locally delivered human plasmin. in Srpski arhiv za celokupno lekarstvo. 2014;142(5-6):342-346.
doi:10.2298/SARH1406342N .

Nenezić, Dragoslav, Radak, Đorđe, Jocić, Dario, Gajin, Predrag, Tanasković, Slobodan, Novaković, Aleksandra, Matić, Predrag, "Thrombolysis of occluded femoropopliteal graft with locally delivered human plasmin" in Srpski arhiv za celokupno lekarstvo, 142, no. 5-6 (2014):342-346,
https://doi.org/10.2298/SARH1406342N . .